Cargando…

Longitudinal CT Imaging to Explore the Predictive Power of 3D Radiomic Tumour Heterogeneity in Precise Imaging of Mantle Cell Lymphoma (MCL)

SIMPLE SUMMARY: Mantle cell lymphoma (MCL) is considered an aggressive lymphoid tumour with a poor prognosis. However, according to recent studies, MCL is more heterogeneous than initially assumed with indolent subtypes without the need for immediate intervention. Currently, there are no routine bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisson, Catharina Silvia, Lisson, Christoph Gerhard, Achilles, Sherin, Mezger, Marc Fabian, Wolf, Daniel, Schmidt, Stefan Andreas, Thaiss, Wolfgang M., Bloehdorn, Johannes, Beer, Ambros J., Stilgenbauer, Stephan, Beer, Meinrad, Götz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773890/
https://www.ncbi.nlm.nih.gov/pubmed/35053554
http://dx.doi.org/10.3390/cancers14020393
Descripción
Sumario:SIMPLE SUMMARY: Mantle cell lymphoma (MCL) is considered an aggressive lymphoid tumour with a poor prognosis. However, according to recent studies, MCL is more heterogeneous than initially assumed with indolent subtypes without the need for immediate intervention. Currently, there are no routine biomarkers for the early prediction of relapse. The urge for personalized medicine has given rise to “radiomics”—the quantification of heterogeneity by imaging based texture analysis which has shown excellent results in numerous fields of application. Our study investigated the potential of CT-derived 3D radiomics as a non-invasive biomarker to risk-stratify MCL patients, thus promoting precision imaging in clinical oncology. ABSTRACT: The study’s primary aim is to evaluate the predictive performance of CT-derived 3D radiomics for MCL risk stratification. The secondary objective is to search for radiomic features associated with sustained remission. Included were 70 patients: 31 MCL patients and 39 control subjects with normal axillary lymph nodes followed over five years. Radiomic analysis of all targets (n = 745) was performed and features selected using the Mann Whitney U test; the discriminative power of identifying “high-risk MCL” was evaluated by receiver operating characteristics (ROC). The four radiomic features, “Uniformity”, “Entropy”, “Skewness” and “Difference Entropy” showed predictive significance for relapse (p < 0.05)—in contrast to the routine size measurements, which showed no relevant difference. The best prognostication for relapse achieved the feature “Uniformity” (AUC-ROC-curve 0.87; optimal cut-off ≤0.0159 to predict relapse with 87% sensitivity, 65% specificity, 69% accuracy). Several radiomic features, including the parameter “Short Axis,” were associated with sustained remission. CT-derived 3D radiomics improves the predictive estimation of MCL patients; in combination with the ability to identify potential radiomic features that are characteristic for sustained remission, it may assist physicians in the clinical management of MCL.